Cabaletta Bio Inc (CABA) - Total Liabilities
Based on the latest financial reports, Cabaletta Bio Inc (CABA) has total liabilities worth $46.13 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Cabaletta Bio Inc (CABA) long-term investment share to see how much of total assets are deployed in long-term investments.
Cabaletta Bio Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Cabaletta Bio Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CABA total asset value.
Cabaletta Bio Inc Competitors by Total Liabilities
The table below lists competitors of Cabaletta Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IGG Inc
F:I91
|
Germany | €1.18 Billion |
|
Korea Petro Chemical Ind
KO:006650
|
Korea | ₩618.86 Billion |
|
Tianjin Realty Development Group Co Ltd
SHG:600322
|
China | CN¥143.24 Million |
|
Hiper Global Ltd
TA:HIPR
|
Israel | ILA110.97 Million |
|
Baotou Dongbao Bio-Tech Co Ltd
SHE:300239
|
China | CN¥831.08 Million |
|
Guanhao Biotech Co Ltd
SHE:300238
|
China | CN¥292.32 Million |
|
Deva Holding AS
IS:DEVA
|
Turkey | TL9.02 Billion |
|
Mahindra Holidays & Resorts India Limited
NSE:MHRIL
|
India | Rs102.45 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Cabaletta Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CABA net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cabaletta Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cabaletta Bio Inc (2017–2025)
The table below shows the annual total liabilities of Cabaletta Bio Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $53.03 Million | +62.12% |
| 2024-12-31 | $32.71 Million | +87.43% |
| 2023-12-31 | $17.45 Million | +40.20% |
| 2022-12-31 | $12.45 Million | +48.54% |
| 2021-12-31 | $8.38 Million | +61.78% |
| 2020-12-31 | $5.18 Million | +64.60% |
| 2019-12-31 | $3.15 Million | -92.99% |
| 2018-12-31 | $44.86 Million | +17845.60% |
| 2017-12-31 | $250.00K | -- |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase synd… Read more